Zenas BioPharma, Inc.
ZBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | -90% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 |
| % Margin | -2,682.8% | 100% | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 |
| % Margin | -3,277.8% | -74.3% | – |
| Other Income/Exp. Net | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | -3,139.8% | -74.2% | – |
| EPS | -3.76 | -0.97 | -3.11 |
| % Growth | -287.6% | 68.8% | – |
| EPS Diluted | -3.76 | -0.97 | -3.11 |
| Weighted Avg Shares Out | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 |
| % Margin | -3,275% | -54.1% | – |